respiratori
virus
common
caus
human
diseas
molecular
detect
techniqu
allow
previous
known
virus
reliabl
identifi
new
virus
discov
molecular
techniqu
realtim
rtpcr
rtrtpcr
perform
individu
viru
combin
multiplex
rtrtpcr
assay
molecular
method
target
singl
analyt
multipl
virus
use
varieti
nucleic
acid
detect
base
strategi
includ
microarray
mass
spectrometri
spectral
distinct
bead
microarray
capillari
electrophoresi
microspher
flow
cytometri
perform
molecular
diagnost
method
either
rtrtpcr
multiplex
assay
typic
evalu
compar
convent
direct
fluoresc
antibodi
dfa
cultur
direct
comparison
report
molecular
assay
moreov
report
laboratori
collabor
compar
method
institut
studi
compar
multiplex
respiratori
viru
panel
respiratori
multicod
assay
rma
eragen
bioscienc
u
wisconsinmadison
rtrtpcr
vanderbilt
univers
detect
common
respiratori
virus
nasal
throat
swab
collect
children
month
old
admit
monro
carel
jr
children
hospit
vanderbilt
septemb
may
acut
respiratori
ill
part
tennesse
children
respiratori
initi
specimen
collect
period
includ
studi
within
four
hour
collect
sampl
divid
aliquot
lysi
buffer
ad
specimen
frozen
separ
unthaw
aliquot
sent
research
laboratori
vanderbilt
univers
univers
wisconsinmadison
rtrtpcr
rma
test
respect
singl
rtrtpcr
experi
perform
follow
virus
respiratori
syncyti
viru
rsv
influenza
b
human
metapneumoviru
hmpv
human
rhinoviru
hrv
parainfluenza
human
coronavirus
netherland
rna
extract
autom
instrument
magnapur
total
nucleic
acid
extract
kit
roch
appli
scienc
refrozen
individu
rtrtpcr
perform
primer
probe
rsv
hmpv
hrv
obtain
publish
literatur
influenza
primer
probe
sequenc
provid
steve
lindstrom
center
diseas
control
prevent
primer
probe
design
use
primer
express
version
appli
biosystem
primer
probe
sequenc
concentr
anneal
temperatur
list
tabl
reaction
mixtur
contain
specimen
rna
test
use
quantitect
probe
rtpcr
kit
qiagen
smart
cycler
ii
cepheid
cycl
condit
min
min
cycl
second
second
tabl
rtrtpcr
assay
optim
character
use
rna
runoff
transcript
capabl
detect
rna
transcript
copiesreact
data
shown
sampl
test
commerci
rtrtpcr
assay
human
betaactin
mrna
appli
biosystem
ensur
rna
integr
rma
multitarget
high
throughput
technolog
integr
multiplex
pcr
microspher
flow
cytometri
luminex
technolog
detect
target
one
reaction
version
assay
includ
viral
target
report
result
virus
test
rtrtpcr
assay
nucleic
acid
extract
trizol
reagent
rma
assay
perform
primer
condit
previous
describ
includ
addit
extern
insect
viru
spike
specimen
control
rna
extract
rt
pcr
site
blind
result
laboratori
data
analyz
order
address
potenti
weak
indic
discord
result
two
assay
first
round
comparison
rtrtpcr
rma
test
modifi
second
round
test
first
round
primer
probe
rsv
hmpv
chang
rtrtpcr
assay
klemenc
et
al
unpublish
data
sampl
retest
two
virus
rma
assay
primer
probe
influenza
modifi
cdna
synthesi
protocol
chang
promega
reagent
appli
biosystem
highcapac
cdna
kit
demograph
clinic
variabl
studi
sampl
describ
frequenc
percent
median
interquartil
rang
iqr
appropri
rma
rtrtpcr
assay
compar
use
test
interrat
agreement
kappa
coeffici
kappa
coeffici
calcul
comparison
valu
data
cell
kappa
consid
indic
good
agreement
bootstrap
use
estim
confid
limit
kappa
cycl
threshold
ct
number
influenza
rsv
compar
group
specimen
use
ttest
first
round
test
rma
detect
rsv
n
rtrtpcr
n
kappa
coeffici
two
test
rma
also
differenti
rsv
subtyp
b
rsv
posit
sampl
detect
rma
rsv
rsv
b
one
sampl
rsv
rsv
b
rsv
identifi
rma
rtrtpcr
detect
rsv
howev
rsv
b
detect
rma
rtrtpcr
detect
rsv
b
sampl
second
round
primer
probe
rsv
rtrtpcr
assay
redesign
base
analysi
publish
viral
sequenc
use
new
primer
probe
rsv
identifi
sampl
rtrtpcr
inter
rater
agreement
rsv
repeat
rtrtpcr
first
rma
rsv
rsv
b
detect
rma
assay
repeat
sampl
analysi
detect
rsv
respect
sampl
posit
rsv
repeat
rtrtpcr
test
neg
rsv
rma
test
mean
ct
specimen
higher
mean
ct
specimen
detect
assay
vs
p
first
round
rtrtpcr
detect
influenza
sampl
rma
detect
influenza
sampl
rtrtpcr
detect
influenza
b
sampl
rma
detect
influenza
b
differ
sampl
second
round
test
influenza
rma
primer
probe
redesign
compar
sampl
posit
influenza
rrtpcr
repeat
rma
assay
detect
posit
sampl
also
detect
rtrtpcr
assay
mean
ct
influenza
specimen
detect
rma
assay
lower
mean
ct
influenza
specimen
vs
p
rtrtpcr
detect
hrv
sampl
compar
rma
detect
hrv
sampl
kappa
coeffici
two
discord
sampl
rtrtpcr
detect
hrv
rma
detect
enteroviru
first
round
test
rma
detect
hmpv
sampl
rtrtpcr
detect
hmpv
sampl
second
round
use
redesign
rtrtpcr
hmpv
primer
probe
hmpv
detect
sampl
concord
result
first
rma
assay
first
rma
assay
detect
hmpv
addit
sampl
detect
repeat
rtrtpcr
assay
one
sampl
posit
hmpv
first
rma
neg
second
set
test
detect
sampl
rma
sampl
rtrtpcr
hcov
detect
sampl
rma
sampl
rtrtpcr
hcov
detect
sampl
either
assay
detect
sampl
rma
sampl
rtrtpcr
piv
detect
sampl
rma
sampl
rtrtpcr
detect
either
method
comparison
first
second
run
rma
assay
summar
tabl
notabl
discrep
run
hrv
rsv
sensit
specif
multiplex
viral
diagnost
assay
gener
compar
viral
cultur
dfa
instead
sensit
rtrtpcr
method
comparison
molecular
method
sensit
molecular
techniqu
rma
rtrtpcr
appropri
determin
whether
sensit
analyt
suffici
clinic
research
use
although
assay
perform
well
select
virus
studi
first
round
comparison
reveal
differ
rate
detect
specif
virus
tabl
rma
assay
detect
significantli
hmpv
rsv
rtrtpcr
assay
detect
influenza
hrv
redesign
primer
led
substanti
improv
detect
hmpv
rsv
rrtpcr
littl
improv
perform
rma
influenza
viru
chang
primer
discord
could
due
sequenc
variat
insuffici
residu
specimen
sequenc
virus
howev
influenza
assay
target
region
matrix
gene
highli
conserv
among
genbank
sequenc
data
shown
mean
ct
influenza
rsv
specimen
detect
rtrtpcr
assay
significantli
higher
detect
rma
assay
suggest
discord
may
due
sensit
two
assay
specimen
lower
viral
load
one
recent
studi
compar
commerci
version
rma
known
plxrespiratori
viral
assay
plxrvp
rtrtpcr
found
good
concord
test
portion
plxrvp
neg
sampl
rma
plxrvp
differ
primer
sequenc
method
use
extract
rna
perform
revers
transcript
factor
import
determin
assay
sensit
given
rna
virus
prone
mutat
current
circul
field
strain
virus
regularli
monitor
sequenc
diverg
would
affect
primer
probe
use
pcrbase
assay
particularli
true
influenza
undergo
consider
variat
everi
year
molecular
assay
often
target
conserv
intern
gene
base
known
sequenc
due
segment
reassort
antigen
shift
new
intern
gene
segment
may
aris
among
influenza
virus
infect
human
multiplex
assay
rma
inclus
two
probe
set
target
two
differ
part
viral
genom
might
elimin
risk
singl
mutat
would
lead
nondetect
studi
limit
first
use
ident
extract
method
primer
rtrtpcr
rma
assay
therefor
discrep
result
could
due
differ
process
primer
design
howev
intent
choic
sinc
specif
goal
studi
compar
two
realworld
method
laboratori
publish
extens
area
respiratori
viru
diagnost
epidemiolog
evalu
independ
method
studi
show
collabor
group
offer
valuabl
tool
assess
assay
perform
imparti
second
use
gold
standard
test
confirm
presenc
absenc
viru
case
discrep
two
assay
explor
option
sequenc
discord
sampl
detect
sequenc
differ
fals
posit
enough
residu
specimen
allow
nonetheless
repeat
test
virus
major
discrep
assumpt
repeat
posit
provid
reassur
posit
sampl
true
posit
third
rtrtpcr
repeat
hmpv
rsv
due
limit
sampl
could
discord
virus
fourth
rma
assay
repeat
alter
influenza
primer
primer
unchang
possibl
chang
influenza
primer
impact
overal
perform
assay
one
import
consider
multiplex
assay
need
reoptim
target
chang
made
primer
use
final
result
evalu
dfa
cultur
though
object
directli
compar
sequencebas
method
summari
virus
test
good
agreement
two
assay
howev
discrep
highlight
need
similar
comparison
molecular
assay
routin
basi
weak
promptli
identifi
correct
investig
may
reluct
make
comparison
might
suggest
defici
particular
method
collabor
studi
critic
advanc
diagnost
methodolog
two
recent
studi
compar
molecular
method
identifi
similar
discrep
addit
clinic
specimen
valid
cultur
respiratori
viru
profici
panel
distribut
qualiti
control
program
like
european
qualiti
control
molecular
diagnost
qcmd
cdc
colleg
american
pathologist
commerci
profici
panel
eg
zeptometrix
respiratori
valid
panel
provid
extern
qualiti
control
clearli
overal
comparison
molecular
method
consid
perform
individu
analyt
goal
studi
determin
best
assay
choic
assay
given
purpos
depend
mani
factor
includ
cost
avail
equip
expertis
sampl
volum
other
multiplex
assay
may
offer
substanti
save
time
cost
due
multipl
analyt
gener
prefer
clinic
test
comparison
molecular
diagnost
method
cultur
dfa
use
establish
valid
ensur
cultiv
virus
correctli
identifi
sequencebas
technolog
howev
data
show
molecular
diagnost
method
also
must
compar
molecular
techniqu
assess
perform
particularli
superior
sensit
molecular
method
compar
cultur
dfa
jame
gern
scientif
advisori
board
stock
option
v
bioscienc
consult
stock
option
eragen
bioscienc
consult
synairgen
centocor
receiv
research
support
astrazeneca
merck
kathryn
edward
receiv
research
fund
sanofipasteur
wyeth
novarti
csl
mari
r
griffin
receiv
grant
support
medimmun
wyeth
john
v
william
serv
consult
medimmun
novarti
serv
scientif
advisori
board
quidel
aa
ekm
perform
rtrtpcr
draft
manuscript
tp
wml
perform
rma
test
aa
tg
perform
statist
analysi
aa
jeg
tvh
kme
mrg
jvw
conceiv
studi
particip
design
coordin
help
draft
manuscript
author
read
approv
final
manuscript
